Orchard Therapeutics
Latest round
- Series C
Last raised
- Aug 2018
Total raised
- $285M
Investors
- 22
About Orchard Therapeutics
Based in London, UK, and founded in 2015 Orchard Therapeutics Limited is a biopharmaceutical company that develops ex vivo gene therapy using patients ' externally modified blood stem cells and transplants them back into the body to correct the genetic disorder. It operates in three geographic regions: The United Kingdom, European Union, and the United States. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio. The company went public in October 2018 (Nasdaq: ORTX).40 million. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. The company's revenue is generated by conducting clinical trials and partners with advocates and organizations.
Who invested in Orchard Therapeutics
22 investors across 3 rounds
See all investors in Orchard Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Orchard Therapeutics
Who invested in Orchard Therapeutics?
Orchard Therapeutics has 22 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Orchard Therapeutics raised?
Orchard Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Orchard Therapeutics last raise money?
Orchard Therapeutics's most recent round on record is a Series C, in Aug 2018.
What does Orchard Therapeutics do?
Based in London, UK, and founded in 2015 Orchard Therapeutics Limited is a biopharmaceutical company that develops ex vivo gene therapy using patients ' externally modified blood stem cells and transplants them back into the body to correct the genetic disorder.
Where is Orchard Therapeutics headquartered?
Orchard Therapeutics is headquartered in London, UK.
Which VCs invest in companies like Orchard Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Orchard Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Orchard Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.